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Background: Colorectal cancer (CRC) remains one of the most common cancers worldwide. We observed that
MUC20 was significantly up-regulated in CRC patients with poor prognosis based on the microarray analysis.
However, little is known about the role of MUC20 in CRC.
Methods: Microarray experiments were performed on the Affymetrix U133 plus 2.0 GeneChip Array. The protein
and mRNA levels of MUC20 were examined by immunohistochemistry (IHC) and Real-Time quantitative PCR
(RT-qPCR) in CRC tissues and adjacent noncancerous tissues (ANCT). ShRNA and overexpression plasmids were used
to regulate MUC20 expression in CRC cell lines in vitro; wound healing, Transwell migration assays, and Western
blotting were used to detect migration and invasion changes.
Results: MUC20 was one of the up-regulated genes in CRC patients with poor prognosis by microarray. Using IHC
and RT-qPCR, we showed that MUC20 expression was significantly higher in CRC tissues than in ANCT (P < 0.05).
We further showed that MUC20 overexpression was correlated with recurrence and poor outcome (P < 0.05). The
Kaplan-Meier survival curves indicated that disease-free survival (DFS) and overall survival (OS) were significantly
worse in CRC patients with MUC20 overexpression. The Cox multivariate analysis revealed that MUC20
overexpression and TNM stage were independent prognostic factors. Elevated expression of MUC20 in cells
promoted migration and invasion, whereas ShRNA-mediated knockdown inhibited these processes. In addition,
Western blotting demonstrated that MUC20-induced invasion was associated with MMP-2, MMP-3, and E-cadherin.
Conclusions: Cumulatively, MUC20 may serve as an important predictor of recurrence and poor outcome for CRC
patients. MUC20 overexpression could enhance migration and invasion abilities of CRC cells. Translation of its roles
into clinical practice will need further investigation and additional test validation.
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reproduction in any medium, provided the orand so on [1-3]. Tumor metastasis is responsible for ap-
proximately 90% of all cancer-related deaths [4,5]. The
molecular pathogenesis and progression of CRC is com-
plicated and poorly understood.
Mucins are large extracellular glycoproteins that are
heavily glycosylated with complex oligosaccharides and
are produced by epithelial cells [6,7]. The core proteins
for human mucins (MUC1-MUC8, MUC12, MUC13,
MUC15-17, and MUC19-21) have been identified [8].
Many mucins, including MUC1, MUC2, MUC4, and
MUC5AC, were abnormally expressed and aberrantly
glycosylated in adenocarcinomas, and were associatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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outcome [9-11]. Previous studies found that up-regulation
of MUC1, down-regulation of MUC2, and up-regulation of
MUC5AC are all involved in the development and progres-
sion of CRC [12-14].
Based on the whole-genome expression profiling of
CRC, we observed that MUC20, a newly recognized
biomarker, was significantly up-regulated in CRC pa-
tients with poor prognosis. MUC20 was first recognized
as an up-regulated novel mucin protein in Immuno-
globulin A nephropathy (IgAN) patients [15]. In IgAN,
MUC20 was a negative regulator of the Met signaling
cascade, which had a role in suppression of the Hepato-
cyte Growth Factor-Induced Grb2-Ras pathway [16].
Although many mucins play crucial roles in tumor
development, no association of MUC20 with CRC has
been reported. In this study, we evaluated MUC20
mRNA/protein expression to determine its prognostic
significance in CRC patients. Furthermore, we ana-
lyzed functions of MUC20 in CRC cell lines by trans-
fection in vitro.Table 1 Part of the differentially up-regulated genes
Probe set ID Gene symble Gene name
226654_at MUC12 Mucin 12, cell surface a
206700_s_at JARID1D Jumonji, AT rich interac
204351_at S100P S100 calcium binding p
231814_at LOC100130716 /// MUC12 Similar to mucin 11 ///
203815_at GSTT1 Glutathione S-transferas
228492_at LOC100130216 /// USP9Y Hypothetical protein LO
peptidase 9, Y-linked (fa
204885_s_at MSLN Mesothelin
207808_s_at PROS1 Protein S (alpha)
223646_s_at CYorf15B Chromosome Y open r
228232_s_at VSIG2 V-set and immunoglob
205174_s_at QPCT Glutaminyl-peptide cyc
236518_at KIAA1984 KIAA1984
214774_x_at TOX3 TOX high mobility grou
203021_at SLPI Secretory leukocyte pep
215108_x_at TOX3 TOX high mobility grou
226622_at MUC20 Mucin 20, cell surface a
228821_at ST6GAL2 ST6 beta-galactosamide
206624_at LOC100130216 /// USP9Y Hypothetical protein LO
peptidase 9, Y-linked (fa
242414_at QPRT Quinolinate phosphorib
204044_at QPRT Quinolinate phosphorib
214983_at TTTY15 Testis-specific transcript
216623_x_at TOX3 TOX high mobility grou
a: FDR false diagnosis rate. P value and FDR was calculated by the modified t test u
signal in patients with poor prognosis and good prognosis.Materials and methods
Patient samples
81 RNAlater-preserved CRC tissues and another 51
paired RNAlater-preserved CRC tissues and ANCT were
obtained from Fudan University Shanghai Cancer Cen-
ter. Additionally, 150 formalin-fixed paraffin-embedded
(FFPE) CRC tissues and ANCT were obtained from the
pathology archives of our Cancer Center. Cancers were
assessed according to the WHO classification. The in-
clusion criteria were as follows: primary sporadic colo-
rectal adenocarcinoma (excluding mucinous carcinoma);
aged from 18 to 75 years; no preoperative chemotherapy
and radiotherapy; similar postoperative chemotherapy
regimens. This study was approved by the Ethical Com-
mittee of our Cancer Center, and written informed con-
sent was obtained from each patient.
Cell culture and reagents
The human CRC cell lines HCT-116, LoVo, and SW620
were cultured in DMEM (GIBCO BRL) supplemented
with 10% FBS, 100 units/mL penicillin, and 100 μg/mLP value FDRa FCb
ssociated 0.001 0.000 2.493
tive domain 1D 0.049 0.012 1.914
rotein P 0.020 0.005 1.881
mucin 12, cell surface associated 0.020 0.005 1.799
e theta 1 0.045 0.011 1.780





eading frame 15B 0.036 0.009 1.690
ulin domain containing 2 0.017 0.003 1.673
lotransferase 0.033 0.008 1.629
0.001 0.000 1.614
p box family member 3 0.025 0.006 1.593
tidase inhibitor 0.034 0.008 1.581
p box family member 3 0.021 0.005 1.578
ssociated 0.005 0.001 1.577
alpha-2,6-sialyltranferase 2 0.010 0.002 1.565
C100130216 /// ubiquitin specific
t facets-like, Drosophila)
0.031 0.008 1.565
osyltransferase 0.028 0.007 1.560
osyltransferase 0.045 0.011 1.560
, Y-linked 15 0.026 0.007 1.559
p box family member 3 0.025 0.006 1.555
sing random variance model (RVM-t test). b: FC fold change, the ratio of probe
Figure 1 Displays the gene expression profiling of 81 CRC tissues. (A) A view of 887 significantly up-expressed genes and 649 significantly
down-expressed genes by hierarchical clustering analysis. Each column represents a sample, and each row represents a gene. Gene expression is
depicted in red (high expression) and green (low expression), respectively. Patients with poor prognosis mainly focus on the left side, and
patients with good prognosis mainly focus on the right side. (B) Expanded view of MUC20 cluster.
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cultured in RPMI 1640 (GIBCO BRL) supplemented
with 10% FBS, 100 units/mL penicillin, and 100 μg/mL
streptomycin. All cells were cultured in a 5% CO2 in-
cubator at 37°C. The primary antibody MUC20 was
purchased from Abcam; MMP3 and E-cadherin were
purchased from Epitomics; MMP2 was purchased from
Bioworld. The secondary antibodies (horseradish per-
oxidase–linked anti-mouse immunoglobulin G, and
anti-rabbit immunoglobulin G) were purchased from
Cell Signaling Technology.
Microarray analysis
Total RNA was extracted from 81 CRC tissues using
TRIzol reagent (Invitrogen). RNA concentration was
assessed with a NanoVue spectrophotometer and RNA in-
tegrity was verified using an Agilent 2100 bioanalyzer. Gene
expression profiling of 81 CRC tissues was performed by
Affymetrix GeneChip Human Genome U133 Plus 2.0 array
platform. Data reading was performed using QuantArray
R software, and data analysis was performed using
Cluster3.0 and SAM2.0 software. After normalization
against the control gene (GAPDH), a gene was desig-
nated as differential if expression in patients with poor
prognosis was > =1.5-fold than in patients with good
prognosis.Tissue microarray and IHC
Tissue microarray (TMA) was constructed using the
specimens from 150 paraffin-embedded blocks of
CRC primary tumors and ANCT. Two CRC tissue
cores and two ANCT cores from the same case were
arranged on a recipient paraffin block (1 mm core).
IHC was performed using the Envision System with
diaminobenzidine (Gene Tech, Shanghai Company
Limited) according to the manufacturer’s protocol.
The working concentration of MUC20 mouse anti-
human polyclonal antibody was 1:100. A granular
cytoplasmic stain was considered as positive. PBS
was used as a negative control.
Tissue microarray slides were blindly evaluated by
two of the authors twice. A staining index (SI, range
0-9) was used to evaluate the results with the follow-
ing formula: SI = intensity * positive area, where in-
tensities were scored as 0 (negative), 1+ (faint/
equivocal), 2+ (moderate), and 3+ (strong). Immuno-
positive areas were categorized as 0 (0%), 1 (<10%), 2
(10-50%), 3 (>50%). When SI ranged from 0 to 2, the
results were defined as negative. If the SI ranged
from 3 to 9, the results were defined as positive [17].
If there are two cores did not yield identical immu-
nostaining, compare them with the whole-section
and select the consistent one.
Figure 2 Illustrates IHC of MUC20 in tissue microarrays (Envision × 40, ×200). (A-B) Representative images of CRC tissues with MUC20
positive expression. (C-D) Representative images of ANCT with MUC20 negative expression.
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Total RNA was extracted from 51 pairs of CRC tissues
and ANCT, and cultured CRC cells using TRIzol reagent
(Invitrogen). Quantitative analysis of MUC20 mRNA ex-
pression was performed in CRC tissues, ANCT, and in
four CRC cell lines. MUC20 was amplified with the follow-
ing primes: 5’-CAA GAT CAC AAC CTC AGC GA -3’
(forward primer) and 5’-ACC TCC ATT TTC ACC TGC
AC-3’ (reverse primer). GAPDH was used as an endogen-
ous control with the following primers: 5’-GAA AGT
CCG GAA GTC TCT GG-3’ (forward primer) and 5’-
TAG AGA CTT GGG CAG TGT GG-3’ (reverse primer).
The cycling conditions for MUC20 and GAPDH were as
follows: one cycle of 95°C for 5 minutes; 40 cycles ofTable 2 MUC20 expression in CRC tissues and ANCT
n MUC20 expression χ2 P
Positive (%) Negative (%)
CRC 150 91(60.7%) 59(39.3%) 76.790 0.000
ANCT 150 18(12.0%) 132(88.0%)95°C for 20 seconds, 58°C for 30 seconds, and 68°C
for 45 seconds; and one cycle of 72°C for 10 minutes.
The specificity of the PCR amplification was validated
by a single peak in the melting curves. Each RT-qPCR
experiment was repeated three times.
Plasmid construction and transfection
The pGPU6/GFP/Neo expression vector was purchased
from Shanghai GenePharma Co. Ltd. The interfering
oligonucleotide designed with a short hairpin structure
targeting MUC20 was cloned into the pGPU6/GFP/
Neo vector. The recombinant vector pGPU6/GFP/Neo-
shRNA-MUC20 was confirmed by DNA sequencing
and enzyme digestion analysis.
The pIRES2-EGFP expression vector was purchased
from Shanghai R&S Biotechnology. The full-length en-
coding cDNA of MUC20 (GenBank accession number
NM_001098516.1) was generated by PCR. The PCR prod-
uct and the pIRES2-EGFP plasmid vector were double
digested with EcoRI/SalI enzymes and then ligated to each
other using T4 DNA ligase. The recombinant vector
Table 3 Correlation of MUC20 expression with
clinicopathologic features in CRC patients
Clinicopathologic
features
n MUC20 expression n (%) χ2 P
Positive Negative
Gender 0.787 0.375
Male 88 56(63.6%) 32(26.4%)
Female 62 35(56.5%) 27(43.5%)
Age(years) 4.261 0.039
<60 94 63(67.0%) 31(33.0%)
> = 60 56 28(50.0%) 28(50.0%)
Tumor size (diameter) 1.189 0.276
<5 87 56(64.4%) 31(35.6%)
> = 5 63 35(55.6%) 28(44.4%)
Location 0.224 0.636
Colon 100 62(62.0%) 38(38.0%)
Rectum 50 29(58.0%) 21(42.0%)
Gross appearance 0.685 0.710
Exophytic 60 34(56.7%) 26(43.3%)
Ulcerative 87 55(63.2%) 32(36.8%)
Diffusely infiltrative 3 2(66.7%) 1(33.3%)
Differentiation 0.086 0.958
High 7 4(57.1%) 3(42.9%)
Moderate 111 67(60.4%) 44(39.6%)
Low 32 20(62.5%) 12(37.5%)
TNM stage 0.264 0.607
II 80 47(58.8%) 33(41.2%)
III 70 44(62.9%) 26(37.1%)
Recurrence 5.849 0.016
Yes 47 36(76.6%) 11(33.4%)
No 90 50(55.6%) 40(44.4%)
Status 5.960 0.015
Survival 93 52(55.9%) 41(44.1%)
Death 41 32(78.0%) 9(22.0%)
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and enzyme digestion analysis. The recombinant vectors
were transfected into CRC cell lines using FuGENE® HD
Transfection Reagent (Roche) according to the manufac-
turer’s instructions.
Wound healing assay
LoVo and SW620 cells were seeded into 6-well plates, cul-
tured until 80% confluent, artificial wounds were gently
made in the plate using a micropipette tip, and the cells
were washed with serum-free medium to remove floating
cells and debris. Representative images of cells migrating
into the wounds were captured at 0 hour and 48 hours in
the same wounded region using an inverted microscope.
Transwell assay
For the invasion assays, Transwell inserts with an 8-μm
pore size for 24-well plates were coated with Matrigel
(ECM550, Chemicon). LoVo and SW620 cells transfected
with pGPU6/GFP/Neo-shRNA-MUC20 or pIRES2-EGFP-
MUC20 were seeded in the upper chamber at 1 - 10 × 105
cells per well in DMEM or RPMI 1640 serum free medium.
Medium with 1% FBS was added in the bottom chamber.
After 12-48 hours, the cells on the upper surface of the fil-
ter were removed using a cotton swab. The cells that had
invaded through the Transwell chamber were fixed with
formaldehyde and stained with 0.1% crystal violet. Ten
high-power fields of each chamber were randomly selected,
and the number of cells was counted using an inverted
microscope.
Western blotting analysis
Whole cell lysates were generated using RIPA lysis buf-
fer (Abcam). Total protein samples were separated using
10% SDS-PAGE gel electrophoresis and then transferred
onto a nitrocellulose membrane. The membrane was incu-
bated with primary antibody at 4°C overnight followed by
horseradish peroxidase-conjugated secondary antibody the
next day for 2 hours at room temperature. The immunore-
active bands were visualized using enhanced chemilumin-
escence with ECL reagents (Pierce). A β-actin antibody
was used as a loading control.
Statistical analysis
The results were presented as the mean ± SEM. The data
were subjected to Student’s test unless otherwise specified
(χ2 test). The Kaplan-Meier survival curves and Log-rank
test were used to compare survival rates. P values less
than 0.05 were considered statistically significant.
Results
Identification of MUC20 from gene expression profiling
Gene expression profiling of 81 CRC tissues were ana-
lyzed using a cDNA based microarray. By using randomvariance model (RVM), we identified 887 significantly up-
expressed genes and 649 significantly down-expressed
genes at significant levels (P < 0.05) between patients with
good prognosis and poor prognosis (Table 1). A supervised
hierarchical cluster analysis was performed as shown in
Figure 1. Many mucins were abnormally expressed in
adenocarcinomas and were associated with carcinogenesis,
tumor invasion, and prognosis, as mentioned before, and we
selected MUC20 (fold change =1.577, P= 0.005, Table 1) as
a newly recognized biomarker to investigate its role in CRC.
Up-regulation of MUC20 was a predictor of poor survival
in CRC
Protein expression MUC20 was determined in 150 paraffin-
embedded CRC tissues and ANCT using IHC. The pattern
Figure 3 Shows the relationship between MUC20 expression, TNM stage and DFS/OS. (A-B) MUC20 overexpression was significantly
associated with DFS and OS. 0: MUC20 not overexpressed; 1: MUC20 overexpressed. (C-D) TNM stage was a significant factor affecting patients’
survival. 2: stage II; 3: stage Ш.
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(Figure 2). The complete data to MUC20 expression was
provided in Additional file 1: Table S1 and Table S2. The re-
sults of IHC showed that MUC20 expression in CRC tissues
(60.7%, 91 of 150) was significantly higher than in ANCT
(12.0%, 18 of 150, P < 0.05, Table 2). Table 3 summarizes the
correlation of MUC20 expression with clinicopathological
features. The patient ages ranged from 18 to 75 years with aTable 4 Univariate regression model of prognostic
covariates in 150 CRC patients
Characteristics DFS OS
χ2 P χ2 P
Gender 0.870 0.351 0.929 0.335
Age 0.477 0.490 0.435 0.510
Location 0.122 0.727 0.216 0.642
Size 0.879 0.349 0.158 0.691
Gross type 0.173 0.917 0.486 0.784
Differentiation 1.423 0.491 4.581 0.032
TNM 9.061 0.003 8.416 0.004
MUC20 expression 5.849 0.016 5.960 0.015median age of 55 years. In this study, 58.7% of patients were
men (88 of 150) and 41.3% were women (62 of 150). Not-
ably, up-regulation of MUC20 was correlated with recur-
rence (P= 0.016) and death (P= 0.015) of CRC patients.
Moreover, younger patients (<60) had a higher expression of
MUC20 than older patients (> = 60, P= 0.039). There was
no relationship between MUC20 expression and gender,
tumor size, location, gross type, and TNM stage.
Mean survival time of CRC patients was 42 months.
The Kaplan-Meier survival curves demonstrated that the
DFS and OS were significantly worse in CRC patients that
overexpressed MUC20 than in patients that did not
overexpress MUC20 (P < 0.05, Figure 3A, 3B). Univariate
analysis (Log-rank test) of prognostic parameters for DFSTable 5 Multivariate Cox regression model for CRC
patients’ survival
Characteristics Exp (B) 95% CI for Exp (B) P
Lower Upper
Differentiation 0.439 0.054 3.547 0.440
TNM 0.400 0.191 0.839 0.015
MUC20 expression 0.241 0.092 0.631 0.004
Figure 4 (See legend on next page.)
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Figure 4 Demonstrates MUC20 mRNA expression and cell migration in vitro (Envision × 40). (A) Relative expression of MUC20 in CRC
tissues and ANCT. The expression of MUC20 was quantified by qRT-PCR and normalized to GAPDH. (B) Relative expression of MUC20 in CRC cell
lines. (C-F) Representative images of the wound healing assay with LoVo transfected with vector and shRNA. Cell migration was photographed
and assessed by measuring gap sizes (inserted number represented percentage area of gap ± SD). (G-J) Representative images of the wound
healing assay with SW620 transfected with vector and pIRES2-EGFP-MUC20. Data represent mean ± SD of triplicates. *: P < 0.05 in a comparison of
the shRNA or pIRES2-EGFP-MUC20 treated group with the mock vector groups.
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overexpressed MUC20 were significantly associated with a
poorer DFS (P = 0.016) and OS (P = 0.015), stage Ш pa-
tients were also significantly associated with a poorer DFS
(P = 0.003) and OS (P = 0.004) (Figure 3C, 3D). Tumor dif-
ferentiation was significantly associated with a poorer OS
(P = 0.032). Multivariate analysis using Cox’s regression
model was performed as shown in Table 5. MUC20Figure 5 Demonstrates influence of MUC20 expression on CRC cell in
quantification of the Transwell invasion assay with LoVo transfected with v
the Transwell invasion assay with SW620 transfected with vector and pIRESoverexpression (P = 0.004) and TNM stage (P = 0.015)
were independent prognostic factors.
MUC20 mRNA expression in tissues and cells by RT-qPCR
The mRNA amounts of MUC20 were calculated by
2^ (-ΔCt) using a relative quantification method. MUC20
mRNA expression was much higher in CRC tissues than
in ANCT (P < 0.001, Figure 4A). The GAPDH was used asvasion (Envision × 200). (A-C) Representative images and
ector and shRNA. (D-F) Representative images and quantification of
2-EGFP-MUC20. *:P<0.05.
Figure 6 Confirms expression levels of MUC20 and metastasis-
related proteins by Western blotting. Enforced expression of
MUC20 increased MMP2 and MMP3 levels, and decreased E-cadherin
level, whereas ShRNA-mediated knockdown had the opposite effect.
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pression of MUC20 in four CRC cell lines. As shown in
Figure 4B, mRNA expression of MUC20 was the highest
in LoVo, the lowest in SW620, and moderate in HCT116
and SW480. Therefore, we chose LoVo for interference
experiments and SW620 for overexpression experiments.
Successful construction of Oligonucleotide and plasmid
transfection
ShRNA interference sequences pGPU6/GFP/Neo-shRNA-
MUC20 were designed and synthesized. The recombinant
vector was confirmed to be correct by restriction enzyme di-
gestion (BamH I and Pst I) and DNA sequencing. The
overexpression plasmid pIRES2-EGFP-MUC20 was digested
by the EcoRI and SalI restriction enzymes. Plasmid digestion
generated two bands: a 5.3 k and a 1.5 k product were
acquired in the electrophoresis lane. DNA sequencing
also confirmed successful construction of the recombin-
ant plasmid.
The transfection efficiency was monitored by green
fluorescent protein (GFP) detection with converted fluor-
escent microscopy after 24-72 hours. The transfection effi-
ciency was calculated as follows: GFP positive cells/total
quantity of cells*100%. The transfection efficiency was the
highest at 48 hours after transfection.
MUC20 promoted migration and invasion abilities of cells
in vitro
To explore whether MUC20 affects the migration and in-
vasion abilities of CRC cells, LoVo and SW620 cells were
transfected with pGPU6/GFP/Neo-shRNA-MUC20 and
pIRES2-EGFP-MUC20, respectively. The wound healing
assay demonstrated that the migratory ability of LoVo
cells transfected with pGPU6/GFP/Neo-shRNA-MUC20
was obviously lower than cells transfected with vector,
while pIRES2-EGFP-MUC20 had the opposite effect
(Figure 4C-4 J). The Matrigel Transwell invasion assay
demonstrated that transfection of pGPU6/GFP/Neo-shRNA-MUC20 significantly reduced the invasive abil-
ity of LoVo cells (Figure 5, P < 0.05). These results
suggested that MUC20 could significantly promote the
migration and invasion ability of CRC cells in vitro.
MUC20 promoted the expression of metastasis related
proteins
MMP-2, MMP-3, and E-cadherin are important metas-
tasis related proteins in CRC [18-21]. To determine
how MUC20 affects invasion and metastasis in CRC
cells, we analyzed the levels of the metastasis related
proteins in cells transfected with either pGPU6/GFP/
Neo-shRNA-MUC20 or pIRES2-EGFP-MUC20. LoVo cells
transfected with pGPU6/GFP/Neo-shRNA-MUC20 showed
a significant reduction in the levels of MMP-2 and MMP-3
and a significant increase in the level of E-cadherin. SW620
cells transfected with pIRES2-EGFP-MUC20 showed the
opposite effect of the transfection in LoVo cells (Figure 6).
This result indicated that MUC20 could affect the expres-
sion of metastasis related proteins, which may further influ-
ence invasion and metastasis abilities of CRC cells.
Discussion
To date, CRC studies have not directly addressed the issue
of accurate prognosis for patients [22-24]. Gene expression
profiling is an innovative and promising approach to investi-
gate the underlying molecular mechanisms. Here, we pro-
filed 81 CRC tissue samples and correlated the expression
profile with patients’ survival and further investigated
MUC20, a new prognostic biomarker in CRC. We demon-
strated that MUC20 was overexpressed in CRC compared
with ANCT. Moreover, MUC20 overexpression was signifi-
cantly correlated with recurrence and death of patients, im-
plicating that MUC20 overexpression can serve as a novel
prognostic marker to identify patients with poor clinical
outcome. We also showed that MUC20 knockdown/
overexpression in CRC cell lines inhibited/enhanced ma-
lignant phenotypes, including migration and invasion.
Collectively, our novel evidence suggested that MUC20
overexpression may involve in CRC aggressive biology.
Many gene expression profiling studies on CRC have
been performed in the last decade using microarray
technology, mainly focusing on carcinogenesis process,
prognosis prediction, and treatment response prediction
[25-27]. Studies on prognosis prediction aim to identify
specific alterations to the gene expression profile that
may be useful to discriminate high risk from low risk
CRC [28]. Arango et al. identified a 17-gene signature
that divides Dukes’C patients into two groups with sig-
nificant different DFS after surgery, and found RHOA
was a prognostic marker that could be used to identify a
subset of patients with poor prognosis who could benefit
from more aggressive treatment [29]. Yamasaki et al.
performed gene expression profiling on 28 primary CRC
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ously or metachronously metastasized CRC and liver me-
tastases, and divided tumors into two classes, localized
and metastasized [30]. Our expression microarray experi-
ments identified 887 significantly up-expressed genes and
649 significantly down-expressed genes from patients with
good and poor prognosis. Most of these genes (MUC12,
S100P, GSTT1, USP9Y, MSLN and so on) are involved in
tumor initiation, progression or metastasis. Among these
differentially expressed genes, MUC20 stood out: it has
been further elucidated as a newly recognized prognostic
biomarker in CRC.
Overexpression of mucins by tumor cells promotes
invasion and metastases. A relationship between mucin
overexpression and poor survival was found in many
human tumors, including ovarian cancer [31], non-
small cell lung cancer [32], and gastric cancer [33]. Pre-
vious studies showed aberrant expression of MUC1,
MUC2, and MUC5AC in CRC [34-36]. Our work is the
first to show that high expression of MUC20 predicts
poor clinical outcome of CRC patients. Our findings
were consistent with recent studies. MUC20 overexpression
predicts poor prognosis in endometrial cancer and en-
hances EGF-triggered invasive behavior through activation
of EGFR–STAT3 pathway [37]. In salivary gland carcinosar-
coma, specific amplifications of MUC20 (in mesenchymal
element) were observed using oligonucleotide microarray-
based comparative genomic hybridization, implying its im-
portant roles in the development of carcinosarcomas [38].
Matrix metalloproteinases (MMPs) are zinc-dependent
proteolytic enzymes involved in every step of tumor me-
tastasis, including tumor growth, migration, host immune
escape, extravasation, angiogenesis, and tumor invasion
[39]. Specifically, high expression levels of certain MMPs,
including MMP2 and MMP3, are involved in the progres-
sion, invasion and metastasis of CRC [40-42]. E-cadherin
plays an essential role in the maintenance of the normal
structure and cell adhesion and is associated with tumor
invasion, and metastasis [43,44]. Reduced or absent
E-cadherin expression has been reported in CRC [45]. To
validate the effect of MUC20 on cell invasion and metastasis,
we successfully constructed the recombinant plasmids for
shRNA interference and overexpression experiments. Ele-
vated expression of MUC20 promoted metastasis of CRC
cells, whereas knockdown of MUC20 attenuated migration
and invasion abilities of CRC cells. We further studied
the effects of MUC20 interference and overexpression
on metastasis related proteins. The results showed that
changes in expression of MMP2 and MMP3 were
consistent with MUC20, whereas E-cadherin was the
opposite. We postulated that MUC20 might be involved
in CRC aggressive biology.
Limitations of this study are the lack of larger-scale
studies due to the small number of available biologicalmaterial and the lack of comparison and integration with
other similar studies. Solving these limitations should be
the main goal in the future, in order to achieve the
translation of promising results into clinical practice.
Conclusion
In summary, this study provided a novel insight into
the role of MUC20 in CRC. As a newly identified bio-
marker, MUC20 may serve as an important predictor
of recurrence and poor outcome for CRC patients.
MUC20 overexpression could enhance migration and
invasion abilities of CRC cells. Translation of its roles
into clinical practice will require further investigation.
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